Lexicon Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€50.13M - Cost of goods sold
€564.56K - Gross profit
€49.57M - SG&A expenses
€79.63M - R&D expenses
€71.50M - EBITDA
-€94.24M - D&A
€366.37K - EBIT
-€101.56M - Interest expenses
€7.64M - EBT
-€103.49M - Tax expenses
-€86.42K - Net income
-€103.49M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€8.80M - Changes in working capital
€16.29M - Operating cash flow
-€87.43M - Capex
€670.10K - Other investing cash flow
€8.54M - Net investing cash flow
€140.05M - Total cash dividends paid
€0.00 - Issuance of common stock
-€76.36K - Debt repayment
€0.00 - Other financing cash flow
-€39.91M - Net financing cash flow
-€39.98M - Foreign exchange effects
€0.00 - Net change in cash
€12.65M - Cash at end of period
€43.21M - Free cash flow
-€86.76M
Balance sheet
- Cash and cash equivalents
€18.33M - Cash and short-term investments
€119.27M - Total receivables
€1.87M - Inventory
€144.14K - Other current assets
€3.20M - Total current assets
€124.48M - Property, plant & equipment
€5.65M - Goodwill
€38.22M - Intangible assets
€0.00 - Long-term investments
€24.88M - Other non-current assets
€315.74K - Total non-current assets
€69.07M - Total assets
€193.55M - Accounts payable
€5.06M - Short-term debt
€779.92K - Other current liabilities
€9.07M - Total current liabilities
€29.89M - Long-term debt
€51.95M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€656.37K - Total non-current liabilities
€52.60M - Total liabilities
€82.49M - Common stock
€314.03K - Retained earnings
-€1.71B - Other equity
-€12.01K - Total equity
€111.06M - Total liabilities and shareholders' equity
€193.55M
Company information
- Market capitalization
€254.29M - Employees
103 - Enterprise Value
€234.16M
Company ratios
- Gross margin
-
98.9% Much worse than peer group: 20,790,314,089,599,805,000.0% - EBITDA margin
-
-188.0% Much worse than peer group: 2,007,440,706,012,113,200.0% - EBIT margin
-
-202.6% Much worse than peer group: 1,721,308,144,879,551,200.0% - EBT margin
-
-206.4% Much worse than peer group: 2,103,534,963,534,940,400.0% - Net margin
-
-206.4% Much worse than peer group: 2,103,534,963,534,941,200.0% - ROE
-
-93.2% Much better than peer group: -479.3% - ROA
-
-53.5% Much better than peer group: -443.0% - Asset turnover
-
25.9% Better than peer group: 15.0% - FCF margin
-
-175.7% Much worse than peer group: 1,191,636,023,778,865,200.0% - FCF yield
-34.6% - Efficiency ratio
288.0% - Net sales per employee
-
€486.74K - Net income per employee
-
-€1.00M